A randomized Phase II, open label multicenter cross-over study, to evaluate biomarkers, in 2nd line treatment of metastatic Castration Resistant Prostate Cancer (mCRPC) with abiraterone and cabazitaxel

Trial Profile

A randomized Phase II, open label multicenter cross-over study, to evaluate biomarkers, in 2nd line treatment of metastatic Castration Resistant Prostate Cancer (mCRPC) with abiraterone and cabazitaxel

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2015

At a glance

  • Drugs Abiraterone acetate (Primary) ; Cabazitaxel (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms AbiCab
  • Most Recent Events

    • 25 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top